Stanley Leong, M.D., Scientist; Chief of Cutaneous Oncology at CPMC, Associate Director of the Melanoma Program, Center for Melanoma Research and Treatment

California Pacific CURRENTS: The online journal of CPMC Research Institute

Developing new approaches to the prognostic assessment and treatment of cutaneous malignancies
  • Metastatic melanoma cells

    Metastatic melanoma cells in a sentinel lymph node. Some patients with primary melanoma will develop metastasis in their lymph nodes. Studies have shown that the extent of spread to the sentinel lymph node (the initial site of regional metastases) is one of the most important prognostic factors in patients with cutaneous melanoma.

+

Research Overview

  • Dr. Leong is board certified in surgery and is a nationally recognized expert in melanoma.
  • He specializes in selective sentinel lymph node dissections, and immunotherapy for patients with advanced melanoma.
  • Dr. Leong has lectured nationally and internationally on new advances in the treatment of malignant melanoma and the use of selective sentinel lymphadenectomy.
  • As Associate Director of CPMC’s Center for Melanoma Research and Treatment, Dr. Leong collaborates with other investigators including Dr. Mohammed Kashani-Sabet on a new integrated research program at CPMCRI aimed at developing novel combination therapies for aggressive and metastatic tumors, including melanomas.

Training
 

Dr. Leong received his M.D. from Tulane University School of Medicine in New Orleans, Louisiana. He conducted residency training in general surgery at the University of California in Irvine, and in internal medicine at the New England Deaconess Hospital in Boston, Massachusetts. Dr. Leong completed three fellowships: surgical oncology at the National Cancer Institute, National Institutes of Health in Bethesda, Maryland; medicine at Harvard Medical School; and surgical oncology and research at Tulane University School of Medicine.


 

Publication Search

Publications

Kashani-Sabet M, Nosrati M, Miller JR 3rd, Sagebiel RW, Leong SPL, Lesniak A, Tong S, Lee SJ, Kirkwood JM, Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690. Clin Cancer Res

Rios-Cantu A, Lu Y, Melendez-Elizondo V, Chen M, Gutierrez-Range A, Fadaki N, Thummala S, West-Coffee C, Cleaver J, Kashani-Sabet M, Leong SPL, Is the non-sentinel lymph node compartment the next site for melanoma progression from the sentinel lymph node compartment in the regional nodal basin? Clin Exp Metastasis

Schuitevoerder D, Leong SPL, Zager JS, White RL, Avisar E, Kosiorek H, Dueck A, Fortino J, Kashani-Sabet M, Hart K, Vetto JT, Is pelvic sentinel node biopsy necessary for lower extremity and trunk melanomas? Am J Surg

Danielsen M, Kjaer A, Wu M, Martineau L, Nosrati M, Leong SP, Sagebiel RW, Iii JR, Kashani-Sabet M, Prediction of positron emission tomography/computed tomography (PET/CT) positivity in patients with high-risk primary melanoma. Am J Nucl Med Mol Imaging

Han D, Thomas DC, Zager JS, Pockaj B, White RL, Leong SP, Clinical utilities and biological characteristics of melanoma sentinel lymph nodes. World J Clin Oncol

VIEW ALL
Stanley Leong, M.D., Scientist; Chief of Cutaneous Oncology at CPMC, Associate Director of the Melanoma Program, Center for Melanoma Research and Treatment
Primary Research Interests
  • Diagnosis, prognosis and treatment of cutaneous malignant melanomas
  • Cancer metastasis and the lymphovascular system

Melanoma Clinical Trials

Research News & Highlights

New high-powered camera to detect cancer being used at CPMC, based on Dr. Leong's research. Dr. Leong was interviewed by ABC News about his use of the camera (Aug. 26, 2016).

Dr. Leong and colleagues published new research in April 2016 on Selective Sentinel Lymph Node Dissection in Lower Extremity Melanoma.